Zhu M - Search Results

1

Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies.

Zhu M, Olson K, Kirshner JR, Khaksar Toroghi M, Yan H, Haber L, Meagher C, Flink DM, Ambati SR, Davis JD, DiCioccio AT, Smith EJ, Retter MW. Zhu M, et al. Clin Transl Sci. 2022 Apr;15(4):954-966. doi: 10.1111/cts.13212. Epub 2022 Jan 7. Clin Transl Sci. 2022. PMID: 34997701 Free PMC article.

2

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.

Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS. Bannerji R, et al. Among authors: zhu m. Lancet Haematol. 2022 May;9(5):e327-e339. doi: 10.1016/S2352-3026(22)00072-2. Epub 2022 Apr 1. Lancet Haematol. 2022. PMID: 35366963 Free PMC article. Clinical Trial.

3

Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies.

Clements JD, Zhu M, Kuchimanchi M, Terminello B, Doshi S. Clements JD, et al. Among authors: zhu m. Clin Pharmacokinet. 2020 Apr;59(4):463-474. doi: 10.1007/s40262-019-00823-8. Clin Pharmacokinet. 2020. PMID: 31679130 Free PMC article. Clinical Trial.

4

Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia.

Zhu M, Kratzer A, Johnson J, Holland C, Brandl C, Singh I, Wolf A, Doshi S. Zhu M, et al. J Clin Pharmacol. 2018 Feb;58(2):168-179. doi: 10.1002/jcph.1006. Epub 2017 Sep 18. J Clin Pharmacol. 2018. PMID: 28922466 Clinical Trial.

5

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.

von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu M, Whitlock JA, Gore L. von Stackelberg A, et al. Among authors: zhu m. J Clin Oncol. 2016 Dec 20;34(36):4381-4389. doi: 10.1200/JCO.2016.67.3301. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27998223 Clinical Trial.

6

Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy.

Kuchimanchi M, Zhu M, Clements JD, Doshi S. Kuchimanchi M, et al. Among authors: zhu m. Br J Clin Pharmacol. 2019 Apr;85(4):807-817. doi: 10.1111/bcp.13864. Epub 2019 Feb 18. Br J Clin Pharmacol. 2019. PMID: 30645768 Free PMC article.

7

Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma.

Hijazi Y, Klinger M, Kratzer A, Wu B, Baeuerle PA, Kufer P, Wolf A, Nagorsen D, Zhu M. Hijazi Y, et al. Among authors: zhu m. Curr Clin Pharmacol. 2018;13(1):55-64. doi: 10.2174/1574884713666180518102514. Curr Clin Pharmacol. 2018. PMID: 29773068 Free PMC article. Clinical Trial.

8

Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.

Zhang Y, Doshi S, Zhu M. Zhang Y, et al. Among authors: zhu m. Br J Clin Pharmacol. 2015 Nov;80(5):957-64. doi: 10.1111/bcp.12663. Epub 2015 May 26. Br J Clin Pharmacol. 2015. PMID: 25912961 Free PMC article. Review.

9

Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.

Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S. Zhu M, et al. Clin Pharmacokinet. 2016 Oct;55(10):1271-1288. doi: 10.1007/s40262-016-0405-4. Clin Pharmacokinet. 2016. PMID: 27209293 Clinical Trial.

10

Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer.

Zhang Y, Kuchimanchi M, Zhu M, Doshi S, Hoang T, Kasichayanula S. Zhang Y, et al. Among authors: zhu m. Br J Clin Pharmacol. 2017 May;83(5):1048-1055. doi: 10.1111/bcp.13179. Epub 2016 Dec 13. Br J Clin Pharmacol. 2017. PMID: 27966237 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14,018 results

Search Page